TORONTO, June 12, 2026 /CNW/ - As FIFA World Cup 2026™ official mobility partner, it's been a long-standing tradition to showcase Hyundai at the world's...
SEATTLE, June 9, 2026 /PRNewswire/ -- Two hundred and fifty nurse practitioners and physician assistants working across multiple clinic locations at Fred Hutchinson Cancer...
OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...
Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ -- It disrupts routines, alters plans, and tests families in...
TAMPA, Fla., June 5, 2026 /PRNewswire/ -- This week, 7-year-old Mikey Hartnett and his parents joined leaders from BayCare and St. Joseph's Children's Hospital...
The expanded Cancer Coach program introduces new survivorship modules building on the latest outcomes showing a 25:1 ROI and ~66% of participants improved physical...
Donor generosity provides lasting support for physician leadership, innovation and patient care in Orange County
ORANGE, Calif., Aug. 13, 2025 /PRNewswire/ -- Today Providence St....
The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...
Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.
Everhope Oncology takes the anxiety out of cancer treatment — with zero wait time, 2X faster service, pre-booked diagnostics, and personalised concierge-led assistance.
GURUGRAM, India,...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).
MILWAUKEE, Aug. 5, 2025 /PRNewswire/ -- Today, the Medical College of Wisconsin (MCW) hosted a ribbon cutting ceremony to celebrate the grand opening of...